Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.39 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.39 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18581592 | 0.88 | HDAC1 (0.54) | HDAC1HDAC6 | |
| SCHEMBL18593267 | 0.87 | MAPT (0.45) | HDAC1HDAC6SMN1; SMN2KDM4EGAA | |
| SCHEMBL3964822 | 0.80 | HDAC1 (0.55) | HDAC1HDAC6 | |
| SCHEMBL18619528 | 0.80 | CYP3A4 (0.48) | SMN1; SMN2KDM4EGAATP53CYP3A4 | |
| SCHEMBL18612596 | 0.80 | CPT2 (0.38) | HDAC1HDAC6KDM4EGAAMRGPRX4 | |
| SCHEMBL28629242 | 0.79 | CYP2C9 (0.50) | HDAC1HDAC6SMN1; SMN2CNR1KDM4E | |
| SCHEMBL18619540 | 0.79 | MAPT (0.57) | SMN1; SMN2KDM4EGAATP53 | |
| SCHEMBL28624625 | 0.77 | GAA (0.47) | HDAC1HDAC6SMN1; SMN2CNR1KDM4E | |
| SCHEMBL18593255 | 0.77 | CPT2 (0.40) | HDAC1HDAC6KDM4EGAACYP3A4 | |
| SCHEMBL18581395 | 0.77 | LMNA (0.47) | HDAC1HDAC6TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190308946-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | VALO HEALTH, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370343-B2 | [6,6] Fused bicyclic HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10029995-B2 | [6,6] fused bicyclic HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2017-03-09 | — | — | US | disclosed |
| WO-2017040963-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | HDAC1 4/4885HDAC6 10/4885SMN1; SMN2 3209/4885 |
| US-10370343-B2 | [6,6] Fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | HDAC1 4/4885HDAC6 10/4885SMN1; SMN2 3209/4885 |
| US-20190308946-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | HDAC1 4/4885HDAC6 10/4885SMN1; SMN2 3209/4885 |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC1, HDAC2 | HDAC1 2/4885HDAC6 10/4885SMN1; SMN2 1525/4885 |
| US-10029995-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | HDAC1 4/4885HDAC6 10/4885SMN1; SMN2 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.